{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T13:54:52Z","timestamp":1766066092033},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,2,15]],"date-time":"2011-02-15T00:00:00Z","timestamp":1297728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s10147-011-0195-5","type":"journal-article","created":{"date-parts":[[2011,2,14]],"date-time":"2011-02-14T05:20:51Z","timestamp":1297660851000},"page":"718-721","source":"Crossref","is-referenced-by-count":18,"title":["Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2\/HER1-negative breast cancer"],"prefix":"10.1007","volume":"16","author":[{"given":"Hideya","family":"Onishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Morisaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Nakafusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Yokohata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuo","family":"Katano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,15]]},"reference":[{"key":"195_CR1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/ctrv.1999.0119","volume":"25","author":"SA Gossman","year":"1999","unstructured":"Gossman SA, Krabak MJ (1999) Leptomeningeal carcinomatosis. Cancer Treat Rev 25:103\u2013119","journal-title":"Cancer Treat Rev"},{"key":"195_CR2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1020200317464","volume":"60","author":"I Cokgor","year":"2002","unstructured":"Cokgor I, Friedman AH, Friedman HS et al (2002) Current opinions for the treatment of neoplastic meningitis. J Neurol Oncol 60:79\u201388","journal-title":"J Neurol Oncol"},{"key":"195_CR3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10072-009-0044-8","volume":"30","author":"P Gaviani","year":"2009","unstructured":"Gaviani P, Silvani A, Corsini E et al (2009) Neoplastic meningitis from breast carcinoma with complete response to liposomal cytarabine: case report. Neurol Sci 30:251\u2013254","journal-title":"Neurol Sci"},{"key":"195_CR4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/B:NEON.0000013462.43156.f4","volume":"66","author":"JL Lee","year":"2004","unstructured":"Lee JL, Kang SJ, Kim TW et al (2004) Leptomeningeal carcinomatosis in gastric cancer. J Neurooncol 66:167\u2013174","journal-title":"J Neurooncol"},{"key":"195_CR5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/annonc\/mdl155","volume":"18","author":"S Beslija","year":"2007","unstructured":"Beslija S, Bonneterre J, Burstein H et al (2007) Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 18:215\u2013225","journal-title":"Ann Oncol"},{"key":"195_CR6","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1186\/bcr2237","volume":"11","author":"DW Miles","year":"2009","unstructured":"Miles DW (2009) When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer. Breast Cancer Res 11:e208","journal-title":"Breast Cancer Res"},{"key":"195_CR7","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684","journal-title":"N Engl J Med"},{"key":"195_CR8","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672","journal-title":"N Engl J Med"},{"key":"195_CR9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792","journal-title":"N Engl J Med"},{"key":"195_CR10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12325-009-0012-y","volume":"26","author":"H McArthur","year":"2009","unstructured":"McArthur H (2009) An overview of HER-targeted therapy with lapatinib in breast cancer. Adv Ther 26:263\u2013271","journal-title":"Adv Ther"},{"key":"195_CR11","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/annonc\/mdm601","volume":"19","author":"HJ Burstein","year":"2008","unstructured":"Burstein HJ, Storniolo AM, Franco S et al (2008) A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 19:1068\u20131074","journal-title":"Ann Oncol"},{"key":"195_CR12","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","volume":"26","author":"NU Lin","year":"2008","unstructured":"Lin NU, Carey LA, Liu MC et al (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26:1993\u20131999","journal-title":"J Clin Oncol"},{"key":"195_CR13","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","volume":"21","author":"W Xia","year":"2002","unstructured":"Xia W, Mullin RJ, Keith BR et al (2002) Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR\/HER2 and downstream Erk1\/2 and AKT pathways. Oncogene 21:6255\u20136263","journal-title":"Oncogene"},{"key":"195_CR14","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/sj.bjc.6605343","volume":"101","author":"M Toi","year":"2009","unstructured":"Toi M, Iwata H, Fujiwara Y et al (2009) Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer 101:1676\u20131682","journal-title":"Br J Cancer"},{"key":"195_CR15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/0008-5472.18.65.1","volume":"65","author":"I Chu","year":"2005","unstructured":"Chu I, Blackwell K, Chen S et al (2005) The dual ErbB1\/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 65:18\u201325","journal-title":"Cancer Res"},{"key":"195_CR16","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2008.18.1925","volume":"27","author":"RS Finn","year":"2009","unstructured":"Finn RS, Press MF, Dering J et al (2009) Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol 27:3908\u20133915","journal-title":"J Clin Oncol"},{"key":"195_CR17","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1158\/0008-5472.CAN-08-0380","volume":"68","author":"ST Lee-Hoeflich","year":"2008","unstructured":"Lee-Hoeflich ST, Crocker L, Yao E et al (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68:5878\u20135887","journal-title":"Cancer Res"},{"key":"195_CR18","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/sj.bjc.6602184","volume":"91","author":"DM Abd El-Rehim","year":"2004","unstructured":"Abd El-Rehim DM, Pinder SE, Paish CE et al (2004) Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 91:1532\u20131542","journal-title":"Br J Cancer"},{"key":"195_CR19","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/bcr2645","volume":"12","author":"LD Hoefnagel","year":"2010","unstructured":"Hoefnagel LD, van de Vijver MJ, van Slooten HJ et al (2010) Receptor conversion in distant breast cancer metastases. Breast Cancer Res 12:R75","journal-title":"Breast Cancer Res"},{"key":"195_CR20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0065-230X(08)60469-8","volume":"55","author":"RS Kerbel","year":"1990","unstructured":"Kerbel RS (1990) Growth dominance of the metastatic cancer cell: cellular and molecular aspects. Adv Cancer Res 55:87\u2013132","journal-title":"Adv Cancer Res"},{"key":"195_CR21","first-page":"1597","volume":"57","author":"T Kuukasjarvi","year":"1997","unstructured":"Kuukasjarvi T, Karhu R, Tanner M et al (1997) Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 57:1597\u20131604","journal-title":"Cancer Res"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-011-0195-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-011-0195-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-011-0195-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T06:20:22Z","timestamp":1685946022000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-011-0195-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,15]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["195"],"URL":"https:\/\/doi.org\/10.1007\/s10147-011-0195-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,15]]}}}